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HOX genes control normal development, primary cellular proc-
esses and are characterized by a unique genomic network organi-
zation. Locus D HOX genes play an important role in limb genera-
tion and mesenchymal condensation. Dysregulated HOXD13
expression has been detected in breast cancer, melanoma, cervical
cancer and astrocytomas. We have investigated the epidemiology
of HOXD13 expression in human tissues and its potential deregu-
lation in the carcinogenesis of specific tumors. HOXD13 homeo-
protein expression has been detected using microarray technology
comprising more than 4,000 normal and neoplastic tissue samples
including 79 different tumor categories. Validation of HOXD13
expression has been performed, at mRNA level, for selected tumor
types. Significant differences are detectable between specific nor-
mal tissues and corresponding tumor types with the majority of
cancers showing an increase in HOXD13 expression (16.1% nor-
mal vs. 57.7% cancers). In contrast, pancreas and stomach tumor
subtypes display the opposite trend. Interestingly, detection of the
HOXD13 homeoprotein in pancreas-tissue microarrays shows
that its negative expression has a significant and adverse effect on
the prognosis of patients with pancreatic cancer independent of
the T or N stage at the time of diagnosis. Our study provides, for
the first time, an overview of a HOX protein expression in a large
series of normal and neoplastic tissue types, identifies pancreatic
cancer as one of the most affected by the HOXD13 hoemoprotein
and underlines the way homeoproteins can be associated to human
cancerogenesis.
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Class I Homeobox genes (Hox, mice; HOX, human) are tran-
scription factors mostly involved in embryonic development.1
They display an unique genomic network organization: 4 compact
chromosomal loci (HOXA at 7p15.3, HOXB at 17q21.3, HOXC at
12q13.3 and HOXD at 2q312) where 39 sequence corresponding
genes can be aligned with each other into 13 antero-posterior
paralogous groups. The HOX gene network, the most repeat-poor
regions in the human genome,3 is also expressed in normal adult
human organs.4 HOX genes appear to regulate phenotype cell iden-
tity,5,6 cell differentiation7,8 and control primary cellular processes,
as proven by the description of congenital,9 somatic10 and meta-
bolic11 diseases involving these genes. Furthermore, besides the al-
ready established role of the HOX network in hematopoiesis and
leukemogenesis,12 HOX genes are implicated in the neoplastic alter-
ations of human solid tissues and organs such as kidney, colon,
lung, skin, bladder, liver, breast and prostate.13,14 New crucial func-
tions have recently been ascribed to HOX genes and homeoproteins
mostly related to their interaction with miRNAs and ncRNAs to
guarantee transcription and export of specific mRNAs.15,16
Locus D HOX genes are localized on chromosome 2q31-32 and
play a role, with its posterior paralogous genes, in limb and digit
generation during embryonic development17 through regulation of
mesenchymal condensation. In this genomic area, a global control
region (GCR) has been identified upstream of the HoxD cluster,
harboring cis-regulatory DNA elements able to coordinate
the expression not only of HoxD genes and their immediate
surroundings but also of phylogenetically unrelated genes
(CREB1, CREB2, Neuro D1) lying several hundred kilobases from
one another.18
The most posterior located HOXD gene, HOXD13, was the first
HOX gene to be described as mutated in human synpolidactyly.19
During normal morphogenesis, HOXD13 is involved in the deter-
mination of the terminal digestive and urogenital tracts.20–22
HOXD13 deregulation has been further detected in different tumor
types, such as breast cancer, melanoma, cervical cancer and atroc-
ytomas,23–26 and in the neuro-endocrine differentiation of human
advanced prostate cancers.27
Here, to immunohistochemically detect the expression of
HOXD13 homeoprotein in normal tissues and its potential deregu-
lation along the evolution of specific tumor types, we utilized tis-
sue microarrays (TMAs) including >4,000 different normal tissue
and cancer sample types from 79 different tumor categories.
HOXD13 expression has been further validated, at mRNA level,
through real-time quantification, for selected tumor types.
We report, for the first time, that an overview of a HOX protein
expression in a large series of normal and neoplastic tissues types
allows the identification of the specific cancer phenotype related
to the HOX protein function. This may represent a general
approach useful for the whole HOX network to underline the role
of the homeoproteins in human cancerogenesis and to allow
potential future clinical applications.
Material and methods
Normal tissue array, multitumor tissue array and
pancreas tissue array
Three different sets of TMA were utilized for our study: a nor-
mal tissue array (NTA) composed of 8 samples of each 76 differ-
ent normal tissue types (n 5 608), a multitumor tissue array (MT-
TMA) composed of up to 50 samples from 79 different tumor
types (n 5 4,018) and a pancreas tissue array (PTA) including 227
ductal carcinomas, 40 samples of pancreatic intraepithelial neopla-
sia (PanIN3) and 40 specimens of normal pancreatic parenchyma
(n 5 307). Distale bile duct carcinomas, ampullary carcinomas
and IPMN-associated carcinomas were not included in the PTA.
All ductal carcinomas of the pancreas were classified according to
the 6th Edition of the TNM classification (UICC).28 Selection and
characteristics of NTA and TMA have been reported elsewhere.29
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TABLE I – COMPARISON OF HOXD13 NUCLEAR HOMEOPROTEIN EXPRESSION IN NORMAL TISSUE AND TUMOR TYPES OF THE
SAME ORGAN (MULTITUMOR ARRAY)
Organ Tissue type Cases (n)
HOXD13 expression
p-value1 Negative Positive p-value2
Mean (%) Median (%)
Adrenal Gland Normal 6 0 0 0.014 6 (100.0) 0 (0.0) 0.014
Cortical adenoma 14 14.3 10 6 (42.9) 8 (57.1) 0.593
Phaeochromocytoma 23 4.3 0 19 (82.6) 4 (17.4) 0.002
Brain Normal 12 1.7 0 <0.001 10 (83.3) 2 (16.7) 0.021
Meningioma 47 4.5 0 35 (74.5) 12 (25.5) <0.001
Astrocytoma 45 12.9 0 24 (53.3) 21 (46.7) 0.655
Glioblastoma multiforme 35 25.1 20 4 (11.4) 31 (88.6) <0.001
Oligodendroglioma 21 22.9 10 8 (38.1) 13 (61.9) 0.275
Endometrium Normal 21 6.5 0 <0.001 14 (66.7) 7 (33.3) 0.127
Endometrioid adenocarcinoma 46 1.3 10 14 (30.4) 32 (69.6) 0.008
Serous adenocarcinoma 32 26.3 30 7 (21.9) 25 (78.1) 0.002
Esophagus Normal 12 3.6 0 0.247 10 (83.3) 2 (16.7) 0.021
Adenocarcinoma 9 8.9 0 6 (66.7) 3 (33.3) 0.317
Squamous cell carcinoma 32 10 0 17 (53.1) 15 (46.9) 0.724
Small-cell carcinoma 1 0 0 1 (100.0)
Gall bladder Normal 9 8.9 0 0.178 7 (77.8) 2 (22.2) 0.096
Adenocarcinoma 44 3.6 0 22 (50.0) 22 (50.0) 1.0
Kidney Normal 24 9.2 10 0.534 20 (83.3) 4 (16.7) 0.001
Clear cell renal cell carcinoma 54 4.6 0 37 (68.5) 17 (31.5) 0.007
Papillary renal cell carcinoma 36 3.3 0 28 (77.8) 8 (22.2) <0.001
Chromophobe renal cell carcinoma 10 2 0 9 (90.0) 1 (10.0) 0.011
Oncocytoma 21 5.2 0 15 (71.4) 6 (28.6) 0.049
Larynx Squamous cell carcinoma 46 19.3 5 23 (50.0) 23 (50.0) 1.0
Liver Normal 20 7.5 0 0.887 16 (80.0) 4 (20.0) 0.007
Hepatocellular carcinoma 85 3.1 0 64 (75.3) 21 (24.7) <0.001
Lung Normal 23 2.7 0 <0.001 18 (78.3) 5 (21.7) 0.007
Squamous cell carcinoma 36 14.4 10 15 (41.7) 21 (58.3) 0.317
Adenocarcinoma 76 11.8 10 33 (43.4) 43 (56.6) 0.251
Large cell carcinoma 18 7.2 5 9 (50.0) 5 (50.0) 1.0
Small cell carcinoma 45 1.1 0 40 (88.9) 5 (11.1) <0.001
Bronchioloalveolar adenocarcinoma 7 14.3 20 2 (28.6) 5 (71.4) 0.257
Lymphoid tissue Normal lymph node 13 1.3 0 0.005 12 (92.3) 1 (7.7) 0.002
Nodular sclerosis Hodgkin lymphoma 25 9.2 0 17 (68.0) 8 (32.0) 0.072
Mixed cellularity Hodgkin lymphoma 17 5.3 0 11 (64.7) 6 (35.3) 0.225
Diffuse large B-cell lymphoma 10 2 0 9 (90.0) 1 (10.0) 0.011
Non-Hodgkin lymphoma, others 55 1.1 0 52 (94.6) 3 (5.4) <0.001
Myometrium Normal 54 7.5 0 <0.001 46 (85.2) 8 (14.8) <0.001
Leiomyoma 55 35.5 30 3 (5.5) 52 (94.6) <0.001
Neuroendocrine
tissue
Typical carcinoid of the lung 37 11.6 10 0.868 14 (37.8) 23 (62.2) 0.139
Extra-adrenal paraganglioma 6 13.3 10 3 (50.0) 3 (50.0) 1.0
Oral cavity Normal 11 3.6 0 0.359 8 (72.7) 3 (27.3) 0.132
Squamous cell carcinoma 39 7.7 0 24 (61.5) 15 (38.5) 0.150
Ovary Normal 4 5.2 2,5 0.863 4 (100.0) 0 (0.0) 0.046
Serous adenocarcinoma 38 18.7 10 11 (29.0) 27 (71.1) 0.009
Mucinous adenocarcinoma 18 14.4 10 5 (27.8) 13 (72.2) 0.059
Endometrioid adenocarcinoma 37 15.7 10 11 (29.7) 26 (70.3) 0.014
Parathyroid Normal 4 0 0 0.238 4 (100.0) 0 (0.0) 0.046
Adenoma 39 2.1 0 34 (87.2) 5 (12.8) <0.001
Peripheral nerves Neurofibroma 35 5.4 0 <0.001 27 (77.1) 8 (22.9) 0.001
Schwannoma 46 17.6 10 14 (30.4) 32 (69.6) 0.008
Pleura Mesothelioma 27 18.1 10 13 (48.2) 14 (51.9) 0.847
Prostate Normal 22 5.7 0 0.007 16 (72.7) 6 (27.3) 0.033
Adenocarcinoma, untreated 50 14.2 10 18 (36.0) 32 (64.0) 0.048
Adenocarcinoma, hormone-refractory 37 8.1 0 19 (51.4) 18 (48.7) 0.869
Skin Normal 25 45 40 <0.001 23 (92.0) 2 (8.0) <0.001
Basal cell carcinoma 65 32.6 30 13 (20.0) 52 (80.0) <0.001
Squamous cell carcinoma 37 8.9 10 17 (46.0) 20 (54.0) 0.622
Malignant melanoma 71 19.4 10 34 (47.9) 37 (52.1) 0.722
Melanocytic naevus 33 34.2 40 7 (21.1) 26 (78.8) <0.001
Fibrous histiocytoma 27 13.7 0 14 (51.9) 13 (48.2) 0.847
Hemangioma 33 30.6 20 3 (9.1) 30 (90.9) <0.001
Kaposi sarcoma 22 45.5 60 0 (0.0) 22 (100.0) <0.001
Appendageal tumours (benign) 18 45 40 0 (0.0) 18 (100.0) <0.001
Small intestine Normal 15 5 40 <0.001 12 (80.0) 3 (20.0) 0.02
Adenocarcinoma 15 21.3 20 3 (20.0) 12 (80.0) 0.02
Soft tissue Normal 8 0 0 0.591 5 (62.5) 3 (37.5) 0.48
Normal, smooth muscle 12 5 0 7 (58.3) 5 (41.7) 0.564
Normal, skeletal muscle 157 3.9 0 149 (94.9) 8 (5.1) <0.001
Lipoma 28 0.71 0 26 (92.9) 2 (7.1) <0.001
Tendon sheath, giant cell tumor 26 38.5 40 2 (7.7) 24 (92.3) <0.001
Leiomyosarcoma 4 32.2 40 6 (13.0) 40 (87.0) <0.001
Liposarcoma 26 24.2 25 7 (26.9) 19 (73.1) 0.019
Pleomorphic sarcoma 29 20.3 10 8 (27.6) 21 (72.4) 0.016
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Briefly, tissue samples were derived from paraffin blocks retrieved
from the archives of the Institute of Pathology, University Hospi-
tal Basel (Switzerland), the Institute of Pathology, University of
Bern (Switzerland) and the Department of Biomorphological Sci-
ences, Section of Pathology, University ‘‘Federico II’’ of Naples
(Italy). All cases were reviewed by experienced pathologists
(L.M.T., L.T., E.K.D.) and representative tissue samples of each
tumor category were chosen for TMA construction. Normal tissue
samples were derived from resection specimens of non-neoplastic
disease and showed a regular architecture of the respective tissue
types.
Tissue microarray construction
Tissue samples were fixed in buffered 4% formalin, embedded
in paraffin, and used to construct a tissue microarray (TMA).
Briefly, hematoxylin-eosin stained sections were made from each
selected primary block (donor blocks) to define representative tis-
sue regions. Tissue cylinders (0.6 mm in diameter) were then
punched from the region of the donor block with the use of a cus-
tom-made precision instrument (Beecher Instruments, Silver
Spring, MD). Tissue cylinders were transferred to a 25 mm 3 35
mm paraffin block to produce the TMA block used for the study.
The resulting TMA block was cut into 3 lm sections that were
transferred to glass slides by use of the Paraffin Sectioning Aid
System (Instrumedics, Hackensack, NJ). Sections from the TMA
block were used for immunohistochemistry.
Immunohistochemistry
Four-micrometer sections of TMA blocks were transferred to
an adhesive-coated slide system (Instrumedics, Hackensack, NJ)
to facilitate the transfer of TMA sections on the slide and to
minimize tissue loss, thereby increasing the number of sections
that can be taken from each TMA block. Standard indirect immu-
noperoxidase procedures were used for immunohistochemistry
(ABC-Elite, Vector Laboratories, Burlingame, CA). A rabbit poly-
clonal antibody was used for HOXD13 detection (1:1,000;
ab19866 Abcam, Cambridge, UK). Optimal staining could be
achieved after steam cooker pretreatment (5 min, 120C) in target
retrieval solution (DAKO, Glostrup, Denmark; pH 9) for antigen
retrieval (3 cycles of 5 min at 650 W). A 3,30-diaminobenzidine
chromogen (liquid DAB; DAKO, Glostrup, Denmark) was used.
Nuclei were counterstained with hematoxilin. HOXD13 antibody
specificity was assessed through the parallel staining of different
MT-TMA slides with paralogous group 13 HOX gene specific
antibodies (HOXA13, HOXB13, HOXC13 and HOXD13) (Can-
tile et al., in preparation). The nuclear staining detected specific
tumor type expression patterns for each antibody and matched
mRNA expression (data not shown). Cytoplasm staining did not
fulfill these criteria. Pancreas–TMA slides were immunostained
for Neuro D1 (sc-20805, 1:150; Santa Cruz Biotechnology,
Santa Cruz, CA), as previously reported.30
Evaluation of immunohistochemistry
Immunoreactivity for HOXD13 and Neuro D1 was scored semi-
quantitatively by evaluating the number of positive nuclei over the
total number of cells. Scores were assigned using 5% intervals and
ranged from 0% to 100%. The reproducibility of this scoring
method between pathologists has previously been demonstrated
for TMAs.31
RNA extraction and analysis
Total RNA was isolated from frozen biopsies, unrelated to
TMA samples, using RNeasy Mini Kit (Qiagen GmbH, Hilden,
Germany) following the manufacturer’s instructions. Samples
were treated with RNase-free DNase (Qiagen GmbH, Hilden, Ger-
many) to prevent amplification of genomic DNA. A total of 1 lg
RNA was subjected to cDNA synthesis for 1 hr at 37C using the
Ready To Go You-Primer First-Strand Beads kit (Amersham Bio-
sciences Europe Gmbh, Freiburg, Germany, cod. 27-9264-01) in a
reaction mixture containing 0.5 lg random hexamers (GeneAmp
RNA PCR Random Hexamers Set N808-0127 Applied Biosys-
tems, Foster City, CA).
Real-time PCR
TaqMan1 analysis was carried out on a 7900HT Sequence
Detection System. Singleplex PCR reactions were performed in
Fast Gene Quantification in 96-Well Plates with The TaqMan Fast
Universal PCR Master Mix (10 ll) in a volume of 20 ll containing
2 ll of cDNA and 1 ll of specific TaqMan Gene Expression Assays
for human HOXD13 (Hs00171253_m1, primers and probe sequen-
ces are Applied Biosystems trademarks), according to the manufac-
turer’s directions. All reactions were performed in triplicate. The
thermal cycling conditions included a step of 20 sec at 95C fol-
TABLE I – COMPARISON OF HOXD13 NUCLEAR HOMEOPROTEIN EXPRESSION IN NORMAL TISSUE AND TUMOR TYPES OF THE
SAME ORGAN (MULTITUMOR ARRAY) (CONTINUED)
Organ Tissue type Cases (n)
HOXD13 expression
p-value1 Negative Positive p-value2
Mean (%) Median (%)
Testis Normal 20 7.5 0 0.912 17 (85.0) 3 (15.0) 0.002
Seminoma 42 6.2 0 23 (54.8) 19 (45.2) 0.537
Non-seminomatous germ
cell tumours
44 7 0 23 (52.3) 21 (47.7) 0.763
Thymus Normal 8 1.25 0 0.164 7 (87.5) 1 (12.5) 0.034
Thymoma 37 11.1 0 26 (70.3) 11 (29.7) 0.014
Thyroid Normal 20 21.9 10 0.052 10 (50.0) 10 (50.0) 1.0
Follicular adenoma 36 14.4 10 5 (13.9) 31 (86.1) <0.001
Follicular carcinoma 51 9.4 10 21 (41.2) 30 (58.8) 0.208
Papillary carcinoma 31 11.9 10 6 (19.4) 25 (80.7) <0.001
Urinary
bladder
Normal 4 13 10 0.003 3 (75.0) 1 (25.0) 0.317
Non-invasive urothelial carcinoma 37 26.5 20 5 (13.5) 32 (86.5) <0.001
Infiltrating urothelial carcinoma 72 13.8 15 27 (37.5) 45 (62.5) 0.034
Uterus, cervix Normal 10 3.6 0 0.038 10 (100.0) 0 (0.0) 0.002
Intraepithelial neoplasia,
high-grade (CIN III)
33 13 10 15 (45.5) 18 (54.6) 0.602
Vulva Squamous cell carcinoma 27 4.4 0 17 (63.0) 10 (37.0) 0.178
The median expression of HOXD13 (10%) was used as a cut-off score to classify cases as negative or positive for HOXD13 protein expres-
sion.
1p-values resulting from comparison of median HOXD13 protein expression levels between tissues of the same organ (Kruskal-Wallis
test).–2p-values resulting from comparison of the number of negative and positive HOXD13 cases for each tissue type (test of equal propor-
tions).
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lowed by a 40 cycles of 95C for 1 sec and 60C for 20 sec. All
reagents were from Applied Biosystems (Foster City, CA).
The comparative Ct method
32 was employed to determine the
human HOXD13 gene variation, using as reference gene TaqMan
Endogenous Controls Human ACTB (b-actin) Endogenous Con-
trol (part number 4352935E Applied Biosystems). We identified a
calibrator cell line that represents the unitary amount of the target
of interest, consequently the samples express n-fold mRNA rela-
tive to the calibrator. Final amounts of target were determined as
follows: target amount 5 22Ct, where Ct 5 [Ct (HOXD13) 2 Ct
(ACTB)]sample 2 [Ct (HOXD13)2 Ct (ACTB)]calibrator.
Statistical analysis
In a first step, HOXD13 immunohistochemistry expression was
evaluated from the multitumor array. For each tissue type and
organ, the mean and median expression of HOXD13, expressed as
a percentage of immunoreactive cells, were noted. The Kruskal-
Wallis test was used to identify differences in median expression
values within the organ.
In a second step, the median expression value of HOXD13
across all tissue types, namely, 10%, was used to classify tissues
as negative or positive for the protein. As the comparison between
negativity and positivity was performed for descriptive purposes
only, rather than for the analysis of clinical endpoints, the selec-
tion of the median value as cut-off score was based on evaluation
of the distribution of HOXD13 scores and is commonly used to
describe semiquantitative measurements.33 Differences in the
number of negative and positive cases were analyzed using a test
of equal proportions.
In a third step, the expression of HOXD13 was evaluated on a
pancreas tumor array complete with clinicopathological informa-
tion and follow-up. Cut-off scores for positivity in this entity were
based on receiver operating characteristic (ROC) curve analysis
which determines the sensitivity and specificity for a binary end-
point, here survival/nonsurvival, at each possible HOXD13 score
thus generating a ROC curve. From the curve, the optimal cut-off
score was selected using the (0,1)-criterion to best discriminate
between survivors and nonsurvivors and the reliability of the cut-
off score was obtained by 200 bootstrapping (resampling) of the
data. The cut-off score was determined to be 0% indicating that
any degree of immunoreactivity was to be considered a positive
case. Survival time differences were analyzed by the Kaplan-
Meier method and log-rank test. As the proportional hazards
assumption was not met for HOXD13 and Neuro D1, Cox regres-
sion analysis could not be performed in multivariable analysis,
therefore stratification of cases by pT stage and pN stage was per-
formed to determine the independent prognostic effect of the pro-
tein markers. Correlation between NeuroD1 and HOXD13 expres-
sion was evaluated by the Spearman Rank correlation. p-values
<0.05 were considered statistically significant. Box-and-whisker
plots of Real Time data were evaluated using R statistical soft-
ware.
Results
HOXD13 expression was evaluated in 3,321 of 4,018 tissue
samples (82.7%). The reason for analysis failure is related to the
TMA technology, including fractions of missing samples or sam-
ples containing only a few tumor cells.
Multitumor array
HOXD13 expression in normal tissue samples. Positive
HOXD13 staining was detected in 93 of 578 (16.1%) valuable
normal tissue samples (Tables I and II). Only pancreas (8 of 16,
50.0%), thyroid (10 of 20, 50.0%), endometrium (7 of 21, 33.3%)
and prostate (6 of 22, 27.3%) demonstrated consistent HOXD13
expression. Adrenal gland, breast, colon, ovary, parathyroid, sali-
vary glands and cervix uteri revealed negative staining in all
investigated cases.
HOXD13 expression in tumor samples. Positivity for HOXD13
was detected in 1,584 of 2,743 (57.7%) valuable neoplastic tissue
samples. Several tumors including Kaposi sarcoma (22 of 22,
100%), pleomorphic adenoma of the salivary glands (37 of 38,
97.4%), adenoma of the colon (94 of 98, 95.9%), leiomyoma of
the myometrium (52 of 55, 94.6%), giant cell tumor of the tendon
sheath (24 of 26, 92.3%), adenocarcinoma of the colon (35 of 38,
92.1%), adenoid cystic carcinoma of the salivary glands (29 of 32,
90.6%) and hemangioma of the skin (30 of 33, 90.9%) showed
HOXD13 expression in more than 90% of the investigated cases
(Tables I and II).
The expression of HOXD13 varied also between distinct tumor
types of particular tissue groups. Invasive lobular and tubular
TABLE II – HOXD13 NUCLEAR HOMEOPROTEIN EXPRESSION IN NORMAL TISSUE AND TUMOR TYPES REPRESENTED IN FIGURES 1 AND 2
Organ Tissue type Cases (n)
HOXD13 expression
p-value1 Negative Positive p-value2
Mean (%) Median (%)
Breast Normal 6 0 0 <0.001 6 (100.0) 0 (0.0) 0.014
Invasive ductal carcinoma 40 23.5 15 11 (27.5) 29 (72.5) 0.004
Invasive lobular carcinoma 38 8.9 0 21 (55.3) 17 (44.7) 0.516
Medullary carcinoma 51 30.4 40 10 (19.6) 41 (80.4) <0.001
Tubular carcinoma 20 17 10 9 (45.0) 11 (55.0) 0.655
Mucinous carcinoma 18 36.1 40 3 (16.7) 15 (83.3) 0.005
Colon Normal 10 0 0 <0.001 10 (100.0) 0 (0.0) 0.002
Adenoma, mild dysplasia 21 17.1 20 1 (4.8) 20 (95.2) <0.001
Adenoma, moderate dysplasia 55 25.6 20 0 (0.0) 55 (100.0) <0.001
Adenoma, severe dysplasia 22 20.7 20 3 (13.6) 19 (86.4) <0.001
Adenocarcinoma 38 29.5 40 3 (7.9) 35 (92.1) <0.001
Salivary gland Normal 20 2.6 0 <0.001 20 (100.0) 0 (0.0) <0.001
Warthin tumour 23 8.3 10 11 (47.8) 12 (52.2) 0.835
Pleomorphic adenoma 38 37.9 40 1 (2.6) 37 (97.4) <0.001
Adenoid cystic carcinoma 32 40.6 0 3 (9.4) 29 (90.6) <0.001
Pancreas Normal 16 20.6 40 <0.001 8 (50.0) 8 (50.0) 1.0
Adenocarcinoma 41 7.1 0 23 (56.1) 18 (43.9) 0.434
Stomach Normal 12 9.3 10 <0.001 7 (58.8) 5 (41.7) 0.564
Adenocarcinoma, diffuse type 17 5.9 0 12 (70.6) 5 (29.4) 0.089
Adenocarcinoma, intestinal type 41 24.6 20 9 (22.0) 32 (78.0) <0.001
The median expression of HOXD13 (10%) was used as a cut-off score to classify cases as negative or positive for HOXD13 protein expres-
sion.
1p-values resulting from comparison of median HOXD13 protein expression levels between tissues of the same organ (Kruskal-Wallis
test).–2p-values resulting from comparison of the number of negative and positive HOXD13 cases for each tissue type (test of equal proportions).
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FIGURE 1 – Nuclear HOXD13 homeopro-
tein expression in the breast: normal tissue
(a), invasive ductal carcinoma (b), medullary
carcinoma (c), mucinous carcinoma (d), co-
lon: normal tissue (e), adenoma (f), adenocar-
cinoma (g), salivary glands: normal tissue
(h), pleomorphic adenoma (i), adenoid cystic
carcinoma (j) (magnification, 3400).
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carcinomas of the breast showed less frequent HOXD13 positivity
than mucinous, medullar and ductal invasive carcinomas (Table
II). In brain tumors, HOXD13 stained glioblastoma multiforme
and oligodendroglioma strongly (mean expression 25.1% and
22.9%, respectively) and meningiomas (mean expression 4.5%)
only weakly (Table I).
Comparison of HOXD13 expression in normal and neoplastic
tissue samples. The expression of HOXD13 varied quantitatively
(16.1% vs. 57.7%) and qualitatively between normal and neoplas-
tic tissue samples of the respective tissue groups. In general, tumor
samples stained more consistently for HOXD13 than their normal
counterparts. HOXD13 was undetectable in normal colonic mu-
cosa but stained positively 94.8% of adenomas and adenocarcino-
mas (Fig. 1). Similarly for salivary glands, a significant increase in
expression was noted in pleomorphic adenomas and adenoid
cystic carcinomas compared to normal submandibular glands (Fig.
1). In skin, only 8% of normal tissues were HOXD13 positive. A
considerable increase in positivity was detected in squamous cell
carcinomas (54% of cases) and histiocytomas (48.2% of cases),
melanoma (52.1% of cases) and appendageal tumors and Kaposi
sarcomas (100% of cases; Table I). Thirty two of the 37 cases of
noninvasive bladder transitional cell carcinomas (TCC) stained
positively for HOXD13 and only with lower frequency in the inva-
sive TCCs and in normal bladder (Table I). In normal prostate,
where HOXD13 has been shown to play a role during normal de-
velopment, a weak staining (6 of 22) was detected. Compared to
hormone-refractory prostate cancers, untreated cancers were more
frequently HOXD13 immunoreactive with 32 of 50 cases demon-
strating positivity (Table I).
In contrast to the general trend, normal pancreas had a signifi-
cant higher mean HOXD13 expression of 20.6% compared to
adenocarcinomas, where only 7.1% of cells stained for the protein
(Fig. 2). Similarly, HOXD13 selectively stained stomach intestinal
adenocarcinomas (mean 24.6%) versus diffuse adenocarcinomas
and normal tissue (Fig. 2).
HOXD13 mRNA quantification in normal tissues and tumors
Differences in HOXD13 expression between normal and tumor
tissues were further validated on 48 selected tissue types, by Real-
Time PCR quantification (Fig. 3). HOXD13 mRNA expression
corresponded substantially to immunohistochemical protein
expression obtained from tissues of the multitumor-TMA. Signifi-
cant increases in HOXD13 mRNA expression were observed
between normal tissues and various tumor types of the same
organ. This was found for brain tumors (glioblastoma multiforme
and oligodendroglioma), endometrium (endometroid and serous
carcinoma compared to normal tissue), submandibular gland
FIGURE 2 – Nuclear HOXD13 homeoprotein expression in the pancreas: normal tissue (a), adenocarcinoma (b,c), stomach: normal tissue (d),
intestinal type adenocarcinoma (e), diffude type adenocarcinoma (f) (magnification, 3400).
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tumors (pleomorphic adenoma and adenoid cystic carcinoma),
breast cancers (medullary and mucinous cancers compared to nor-
mal tissue), adenocarcinoma and bronchoalveolar lung carcinoma,
melanoma and liposarcoma with respect to normal fat and lipo-
mas. The progressive increase in HOXD13 mRNA expression was
most apparent for tissues of the colon with lowest levels in normal
tissues, followed by increased expression in dysplastic tissues and
maximum expression in adenocarcinomas. Only in normal pan-
creas and stomach does HOXD13 mRNA appear hyper-expressed
with respect to pancreas adenocarcinoma and diffuse stomach
adenocarcinoma.
Pancreatic tissue array
Association of HOXD13 expression with prognosis. Of the
patients with pancreatic ductal carcinoma, whose biopsies are
included in the pancreas TMA, 64 had information on survival.
The overall 12-month survival rate for these patients in our study
was 52.4% (95% CI: 41–63%). Stratifying by HOXD13, patients
with negative protein expression (n 5 29) had a considerable
more adverse survival time compared to patients with positive
protein expression (n 5 35). The 12-month survival rates were
17.2% (95% CI: 6–33%) and 79.8% (95% CI: 62–90%) for nega-
tive and positive cases, respectively (p < 0.001; Fig. 4).
Of the 64 patients with survival information, pT stage was
available in 62, of whom 13 had pT1 or pT2 tumors and 49 were
diagnosed with pT3 or pT4 disease. Stratifying by pT stage, nega-
FIGURE 3 – HOXD13 gene expression by qRT-PCR. Box plots represent the range of HOXD13 comparative expression values (normal and tu-
mor vs. calibrator) analyzed in 13 groups of tissues [48 subgroups (n  3)]. Axes represent tumor types versus mRNA fold increase. Grey plots
are normal tissues.
FIGURE 4 – Kaplan–Meier survival curve of HOXD13 expression in
pancreatic cancer. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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tive HOXD13 expression led to significantly worse outcome com-
pared to positive expression of the protein in pT1 or pT2 patients
(p < 0.001) and also in pT3 or pT4 patients (p 5 0.012) indicating
that the adverse effect of negative HOXD13 expression on prog-
nosis was independent of pT stage.
Information on lymph node metastasis was available in 58
patients of whom 39 had positive lymph nodes (>pN0 disease)
and 19 were free of involvement (pN0 disease). In both patients
with and without lymph node metastasis, negative expression of
HOXD13 led to highly adverse outcome compared to positive
HOXD13-expressing cases (p < 0.001 and p 5 0.018, respec-
tively). These results suggest that the effect of negative HOXD13
expression is associated with an adverse outcome regardless of
lymph node status.
Differential expression in normal tissues, PanIN and cancer
Differences in the mean HOXD13 expression were evaluated
between normal tissue, PanIN and carcinoma. The mean expres-
sion was 52% in normal tissue and 19% and 17% in PanIN and
carcinoma, respectively (p < 0.001) underlining a decreased HOX
D13 expression with tumor progression.
Neuro D1 expression
Neuro D1 positivity was linked to more adverse survival time
with 12-month survival rates of 59.3% and 63.6% for patients
with positive and negative tumors, respectively (p 5 0.044). This
prognostic effect was not found to be independent of T and N
stage or of HOXD13 expression. In addition, analysis of HOXD13
and Neuro D1 immunohistochemistry scores were significantly
and negatively correlated (r 5 20.21; p 5 0.009). The mean
Neuro D1 expression in normal tissues, PanIN and carcinomas
was 36%, 62% and 59%, respectively, indicating a significant
increase in Neuro D1 expression with tumor progression (p <
0.001).
Discussion
Posterior located genes in the HOX network (paralogous 13
HOX genes) generate life-compatible phenotypes, such as synpo-
lydactyly and hand-foot-genital syndrome due to HOXD1319 and
HOXA13 mutations,9 respectively. Paralogous 13 group HOX
genes have also been connected to cell proliferation: HOXA13
with hepatocellular carcinoma evolution, HOXB13 with breast
cancer progression,34,35 HOXC13 with hair follicle growth and
melanoma progression36 and HOXD13 with prostate development
and cancerogenesis.22,27 HOXA13, HOXC13 and HOXD13 further
generate chimerical fusion proteins with Nup 98 involved in
human leukemias.37
Nuclear HOXD13 homeoprotein expression is detectable in
normal stomach, pancreas, small intestine, urinary bladder, kid-
ney, prostate, testis, endometrium, ovary and uterus. These local-
izations are consistent with the role of HOXD13 during normal de-
velopment controlling the morphogenesis of the terminal part of
the body including digestive and urogenital tracts.20 Thus, our
data support the involvement of HOXD13 with gene programs
associated with embryonic and adult cell physiology of posterior
tissues and organs.
The nuclear HOXD13 expression in 79 tumor types stains spe-
cific cancer phenotypes within an organ: meningiomas among
brain tumors, medullary and mucinous phenotypes within breast
cancers, endometrioid carcinomas among endometrial cancers,
lung small cell cancers within lung tumors, stomach intestinal car-
cinomas among stomach adenocarcinomas, thyroid papillary can-
cers within thyroid follicular cancers.
Comparison of Multi-Normal and Multi-Tumor-Tissue-Array
staining allows the identification of 19 tissues and organs display-
ing a differential HOXD13 homeoprotein expression. HOXD13
homeoprotein expression matches HOXD13 mRNA expression as
detected through real-time PCR on normal tissues and selected
cancer phenotypes. The general trend supports an increased
FIGURE 5 – Systematic approach
undertaken to study the role of
HOXD13 in human cancers. [Color
figure can be viewed in the online
issue, which is available at www.
interscience.wiley.com.]
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HOXD13 homeoprotein expression in cancer biopsies with respect
to normal tissues.
HOXD13 expression is silent in normal breast whereas charac-
terizes medullary and mucinous breast cancer types. It has recently
been reported that the expression-ratio of HOXB13:IL17BR is a
strong, independent predictor of treatment outcome in the setting
of adjuvant tamoxifen therapy of breast cancer patients.38 Paralo-
gous group HOX genes are known to complete each other in per-
forming redundant and additive functions. This has already been
proven to occur between HOXD13 and HOXB13 role in different
tumor types.24,39
In colon cancer, HOXD13 expression appears to be related to
tumor progression. Several observations have documented the role
of Hox genes in the patterning of the mammalian gastrointestinal
tract. Systematic expression profiles have located a Hox code with
specific Hox genes, including HoxD genes, in intestine regionali-
zation.40
Deregulated HOXD13 expression in several adenocarcinomas
on our MT-TMA suggests the potential involvement of this gene
with the neoplastic transformation of glandular epithelia. This ob-
servation is supported by the described alterations, consequent to
HoxD13 loss of function, during the embryonic development of
mutant mice, in the generation of posterior glandular epithelia
(ampullary gland, urethral glands, bulbourethral gland, coagulat-
ing gland, dorsal and ventral prostate, glandular folding of seminal
vesicles41).
HOXD13 homeoprotein expression decreases from normal to
tumor tissues only in stomach and pancreas. Interestingly, this ob-
servation has been confirmed by the detection in pancreas TMA
that HOXD13 homeoprotein expression has a significant effect on
the prognosis of patients with pancreatic cancer. This effect on
outcome is independent of the patients’ T or N stage at the time of
diagnosis and is in opposition with Neuro D1 expression.
HOXD13 is a better prognostic factor than Neuro D1 for pancre-
atic cancer. We acknowledge, however, that these preliminary
findings require validation on a lager cohort of patients and by
other groups, due to the sample size of the pancreatic patients in
our study and to their relatively short follow-up times.
The chromosomal area 2q31-33 in which the HOXD locus is
located houses the interactors of cyclic AMP (CREB1, CREB2
and cAMPGEFII), specifically active in the developing brain and
regulating exocytosis in secretory cells. This same chromosomal
area, coordinately regulated by GCR (see introduction), contains
the prostate-specific androgen-related gene PCGEM1, a miRNA
whose expression increases in high-risk prostate cancer patients.42
In physical contiguity with PCGEM1 is located the gene Neuro
D1, whose ectopic expression causes conversion of epithelial
cells into neurons43 and is actively expressed in advanced prostate
cancer.30 Neuro D1 is further able to interact with the insulin pro-
moter44 and is between major players of pancreas organogenesis
as is expressed in all differentiated and postmitotic pancreatic en-
docrine cells. It has been postulated that the involvement of
Neuro D1 in promoting cell cycle exit inducing pancreatic pro-
genitor cells to differentiate.45 Thus, HOXD13 deregulation in
brain, prostate and pancreatic cancers appears to be related to the
neurogenic and neuroendocrine characteristics of this genomic
landscape.
In conclusion, our data identify, through the detection of
HOXD13 homeoprotein expression in 79 types of cancer and the
validation with parallel mRNA expression, the prognostic role of
HOXD13 in pancreatic cancer. Such a systematic approach, as
summarized in Figure 5, may represent a useful methodology for
future studies aimed at depicting the role of other members of the
HOX network in human cancers. Deregulation of HOXD13 sup-
ports the important role of HOX genes in tumor evolution and rep-
resents a starting point for the integrated analysis of specific can-
cer series, to use HOX genes as potential diagnostic, prognostic
and predictive markers.
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